I tried to delete a part of this document (contents below):
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23121439</PMID>
<DateCreated>
<Year>2012</Year>
<Month>11</Month>
<Day>29</Day>
</DateCreated>
<DateCompleted>
<Year>2012</Year>
<Month>12</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised>
<Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1533-4406</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>367</Volume>
<Issue>22</Issue>
<PubDate>
<Year>2012</Year>
<Month>Nov</Month>
<Day>29</Day>
</PubDate>
</JournalIssue>
<Title>The New England journal of medicine</Title>
<ISOAbbreviation>N. Engl. J. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Bedside monitoring to adjust antiplatelet therapy for coronary stenting.</ArticleTitle>
<Pagination>
<MedlinePgn>2100-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1209979</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients' responses to oral antiplatelet therapy are subject to variation. Bedside monitoring offers the opportunity to improve outcomes after coronary stenting by individualizing therapy.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We randomly assigned 2440 patients scheduled for coronary stenting at 38 centers to a strategy of platelet-function monitoring, with drug adjustment in patients who had a poor response to antiplatelet therapy, or to a conventional strategy without monitoring and drug adjustment. The primary end point was the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 year after stent implantation. For patients in the monitoring group, the VerifyNow P2Y12 and aspirin point-of-care assays were used in the catheterization laboratory before stent implantation and in the outpatient clinic 2 to 4 weeks later.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">In the monitoring group, high platelet reactivity in patients taking clopidogrel (34.5% of patients) or aspirin (7.6%) led to the administration of an additional bolus of clopidogrel, prasugrel, or aspirin along with glycoprotein IIb/IIIa inhibitors during the procedure. The primary end point occurred in 34.6% of the patients in the monitoring group, as compared with 31.1% of those in the conventional-treatment group (hazard ratio, 1.13; 95% confidence interval [CI], 0.98 to 1.29; P=0.10). The main secondary end point, stent thrombosis or any urgent revascularization, occurred in 4.9% of the patients in the monitoring group and 4.6% of those in the conventional-treatment group (hazard ratio, 1.06; 95% CI, 0.74 to 1.52; P=0.77). The rate of major bleeding events did not differ significantly between groups.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study showed no significant improvements in clinical outcomes with platelet-function monitoring and treatment adjustment for coronary stenting, as compared with standard antiplatelet therapy without monitoring. (Funded by Allies in Cardiovascular Trials Initiatives and Organized Networks and others; ARCTIC ClinicalTrials.gov number, NCT00827411.).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Collet</LastName>
<ForeName>Jean-Philippe</ForeName>
<Initials>JP</Initials>
<AffiliationInfo>
<Affiliation>Institut de Cardiologie Hôpital Pitié–Salpêtrière and Université Pierre et Marie Curie, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Cuisset</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rangé</LastName>
<ForeName>Grégoire</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cayla</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Elhadad</LastName>
<ForeName>Simon</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pouillot</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Henry</LastName>
<ForeName>Patrick</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Motreff</LastName>
<ForeName>Pascal</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Carrié</LastName>
<ForeName>Didier</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Boueri</LastName>
<ForeName>Ziad</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Belle</LastName>
<ForeName>Loic</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Van Belle</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Rousseau</LastName>
<ForeName>Hélène</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Aubry</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Monségu</LastName>
<ForeName>Jacques</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sabouret</LastName>
<ForeName>Pierre</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Connor</LastName>
<ForeName>Stephen A</ForeName>
<Initials>SA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Abtan</LastName>
<ForeName>Jérémie</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kerneis</LastName>
<ForeName>Mathieu</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Saint-Etienne</LastName>
<ForeName>Christophe</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Barthélémy</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Beygui</LastName>
<ForeName>Farzin</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Silvain</LastName>
<ForeName>Johanne</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Vicaut</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Montalescot</LastName>
<ForeName>Gilles</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<CollectiveName>ARCTIC Investigators</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT00827411</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2012</Year>
<Month>11</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>N Engl J Med</MedlineTA>
<NlmUniqueID>0255562</NlmUniqueID>
<ISSNLinking>0028-4793</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C446540">thienopyridine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>A74586SNO7</RegistryNumber>
<NameOfSubstance UI="C055162">clopidogrel</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>G89JQ59I13</RegistryNumber>
<NameOfSubstance UI="D000068799">Prasugrel Hydrochloride</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>OM90ZUW7M1</RegistryNumber>
<NameOfSubstance UI="D013988">Ticlopidine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>R16CO5Y76E</RegistryNumber>
<NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2013 Feb 28;368(9):871</RefSource>
<PMID Version="1">23445102</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>Nat Rev Cardiol. 2013 Jan;10(1):2</RefSource>
<PMID Version="1">23165070</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2013 Feb 28;368(9):870-1</RefSource>
<PMID Version="1">23445101</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn">
<RefSource>N Engl J Med. 2013 Feb 28;368(9):871-2</RefSource>
<PMID Version="1">23445100</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003327" MajorTopicYN="N">Coronary Disease</DescriptorName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003328" MajorTopicYN="N">Coronary Thrombosis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019095" MajorTopicYN="Y">Point-of-Care Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000068799" MajorTopicYN="N">Prasugrel Hydrochloride</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015607" MajorTopicYN="Y">Stents</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013876" MajorTopicYN="N">Thiophenes</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013988" MajorTopicYN="N">Ticlopidine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
</MeshHeading>
</MeshHeadingList>
<InvestigatorList>
<Investigator ValidYN="Y">
<LastName>Montalescot</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Collet</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Coste</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Le Breton</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Elhadad</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Cohen</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Wittenberg</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Leclercq</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Varenne</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Ledermann</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Cayla</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Cuisset</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Van Belle</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Henry</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Bassand</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Finet</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Paganelli</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Carrié</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Aleil</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Belle</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Brunel</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Rangé</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Pansieri</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Barney</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Lhoest</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Levai</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Caussin</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Tibi</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Zemour</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Delarche</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>D'Houdain</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Christiaens</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Pouillot</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Casteigt</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Ferrari</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Cottin</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Ohlmann</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Pecheux</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Sayah</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Motreff</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Champagnac</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Py</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Shadfar</LastName>
</Investigator>
<Investigator ValidYN="Y">
<LastName>Boueri</LastName>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2012</Year>
<Month>11</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2012</Year>
<Month>11</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>12</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23121439</ArticleId>
<ArticleId IdType="doi">10.1056/NEJMoa1209979</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>
And I wrote this to delete everything between the tags InverstigatorList
, but the content of this tag still remains.
$str = preg_replace('/<InvestigatorList>[\s\S]*?<\/InvestigatorList>/', "", $str);